The American Journal of Managed Care

AstraZeneca’s Camille Hertzka: Testing for HRR Mutation Status in mCRPC Helps Inform Risk Profile

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, discusses why it is important to test for HRR gene mutation status and appropriateness of olaparib use in patients with ...
ascopubs.org

Real-world homologous recombination repair (HRR) mutation testing patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in the United States (US).

Real world (rw) homologous recombination repair (HRR) gene mutation testing trends in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the United States (US). This is an ...
The Korea Herald

IMBdx Expands Targeted Therapies Agreement Following Successful Evaluation of Blood-Based Genomic Profiling Assay in Prostate Cancer

SEOUL, South Korea, June 8, 2023 /PRNewswire/ -- IMBdx Inc., a premier precision cancer diagnostic company accredited by CAP, announced today its plans to broaden its collaboration with AstraZeneca, a ...
Nature

A novel test of informative missingness using inconsistent linkage disequilibrium signals between case-parent triads and incomplete data

In general, multiple issues are examined before the analysis of genetic data such as Hardy–Weinberg Equilibrium and Mendelian errors. Although missing genotypes are commonly observed in genetic ...